Biogen Inc

Pharmaceuticals

BIIB

$ 290 (0.63)%

Share price

$ 42 bn

Market Cap

$ 43 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.06x the weighted average for S&P 500

FY2021

Primary Climate Goal

Proj. YOY change in GHG emissions (Scope 1 + 2)

Weaker than the -6.6% weighted average for S&P 500

FY2022

Biogen Inc aims to reduce Scope 1 + 2 by 55% by 2032 from a base year 2019

1.5°C

GHG emissions and Carbon intensity

Biogen Inc reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 97 Kt (+2.9/+3.1% y-o-y). Carbon intensity also surged to 8.9 t (+1.9/+27% y-o-y).

Biogen Inc's Scope 3 emissions increased to 406 Kt (+58/+16% y-o-y). The parameter has been fairly volatile.

The company is committed to reducing Scope 1 + 2 by 55% by 2032 from a base year 2019, which translates into the estimated reduction of -4.6 Kt per annum over the period of FY2022 - FY2032. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Date	Total CO2e emissions (location-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2021Q4	97	63	34	406	10,982	8.9
2020Q4	95	58	37	349	13,445	7
2019Q4	105	67	38	425	14,378	7.3
2018Q4	106	68	37	436	13,453	7.9
2017Q4	103	62	41	482	12,274	8.4
2016Q4	108	62	46	255	11,449	9.4
2015Q4	98	60	38	262	10,764	9.1

Biogen Inc

Carbon footprint

Primary Climate Goal

Biogen Inc aims to reduce Scope 1 + 2 by 55% by 2032 from a base year 2019

GHG emissions and Carbon intensity

Biogen Inc's carbon footprint

Company environmental metrics